Kaskela Law LLC is investigating POINT Biopharma Global (NASDAQ: PNT) on behalf of the company’s former employees.

On July 1, 2021, Therapeutics Acquisition Corp. (“Therapeutics Acquisition”), a publicly traded special purpose acquisition (“SPAC”) company, announced that Therapeutics Acquisition’s stockholders had approved of an acquisition of privately held POINT Biopharma Inc. (“Legacy POINT”).  Therapeutics Acquisition also announced that, upon the closing of the acquisition, the combined company would be renamed  POINT Biopharma Global (“POINT Biopharma”) and its common stock would start trading under ticker symbol NASDAQ: PNT.

In connection with the closing of the acquisition, many of Legacy POINT’s executives and employees had their previously held shares/stock options of privately held Legacy POINT converted into shares of publicly traded POINT Biopharma (NASDAQ: PNT).  The investigation seeks to determine whether this share conversion was done in a fair manner and in accordance with the securities laws, or whether former Legacy POINT shareholders were financially harmed in connection with the conversion.

Former Legacy POINT employees who had their shares/stock options of privately held Legacy POINT converted into publicly traded shares of POINT Biopharma (NASDAQ: PNT) are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, to receive additional information about this investigation and their legal rights and options.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750